- Home
- CMMB vs XAIR Comparison
CMMB vs XAIR Comparison
Compare CMMB & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | XAIR |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.1M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMMB | XAIR |
|---|---|---|
| Price | $1.86 | $0.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $10.00 |
| AVG Volume (30 Days) | 73.0K | ★ 184.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | 62.09 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | $45.75 | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.87 | $0.15 |
| 52 Week High | $3.86 | $3.78 |
Technical Indicators
Market Signals| Indicator | CMMB | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 36.34 |
| Support Level | $1.48 | $0.67 |
| Resistance Level | $1.85 | $1.25 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.26 | 21.07 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.